"I may have been swayed if this represented a major advance in the field," said panelist Walter Dunn, MD, PhD, of the ...

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with ...

Which drug combinations are best for prevention of nausea and vomiting caused by chemotherapy in adults with cancer?

Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report second-quarter 2025 results on July 17. The Zacks Consensus Estimate for revenues is pegged at $14.04 billion, while the same for earnings ...

Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell ...

Antibody–drug conjugates (ADCs) are advanced cancer therapeutics that combine an antibody-based delivery system with a cytotoxic payload through chemical linkers. Anthraquinone-fused enediyne (AFE) ...

Our conclusions The results of our analysis suggest that there is no superior drug combination for prevention of CINV for people receiving HEC or MEC. However, results suggest that the choice of drugs ...

Most two-drug combination regimens or three-drug combination regimens have better PFS outcomes compared to chemotherapy regimens. In the monotherapy, there were no significant differences between PD-1 ...